Response #1 to Discussion Post (week 4).pdf - NURS 6521N-26 ADVANCED PHARMACOLOGY RESPONSE 1 to DISCUSSION POST(Week 4 Misty Ledesma(Scenario COPD

Response #1 to Discussion Post (week 4).pdf - NURS 6521N-26...

This preview shows page 1 - 2 out of 2 pages.

NURS 6521N-26: ADVANCED PHARMACOLOGY RESPONSE # 1 to DISCUSSION POST (Week 4): Misty Ledesma (Scenario: COPD) Deborah Lucero, RN, BS, CVRN-BC, FACCN Pharmacotherapy for Respiratory Disorders Dear Misty, Your discussion post regarding chronic obstructive pulmonary disease (COPD) is informative and well explained. I feel like we, as practitioners should emphasize smoking which continue to be the most important preventative therapeutic intervention for COPD. The patients diagnosed with COPD are either former smoker or current smokers. The risk of dying from COPD is 30 tomes higher among smokers (Arcangelo, 2013). Varenicline (Chantix), a partial agonist selective for alpha-4, beta-2 nicotinic acetylcholine receptor, its mechanism of action is thought to result from activity at the neuromuscular nicotinic receptor synapsis, where it chemically binds and produces agonist activity while simultaneously preventing nicotine binding (Mosenifar, 2016). Agonistic activity is significantly lower than nicotine binding.
Image of page 1
Image of page 2

You've reached the end of your free preview.

Want to read both pages?

  • Summer '15
  • Chronic obstructive pulmonary disease, Nicotinic acetylcholine receptor

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture